Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisation.
Solà-Morales, O., Volmer, T., Mantovani, L. (2019). Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. JOURNAL OF MARKET ACCESS & HEALTH POLICY, 7(1) [10.1080/20016689.2018.1562861].
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
Mantovani, Lorenzo
2019
Abstract
Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisation.File | Dimensione | Formato | |
---|---|---|---|
10281-279820.pdf
accesso aperto
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Dimensione
978.09 kB
Formato
Adobe PDF
|
978.09 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.